Florez-Alvarez L, de Souza E, Botosso V, de Oliveira D, Ho P, Taborda C
Front Microbiol. 2022; 13:1040093.
PMID: 36386719
PMC: 9640979.
DOI: 10.3389/fmicb.2022.1040093.
Wang Y, Li J, Hu Y, Liang Q, Wei M, Zhu F
Hum Vaccin Immunother. 2016; 13(1):153-168.
PMID: 27764560
PMC: 5287303.
DOI: 10.1080/21645515.2016.1225637.
Roddy P
Viruses. 2014; 6(10):3699-718.
PMID: 25271875
PMC: 4213557.
DOI: 10.3390/v6103699.
Nakayama E, Saijo M
Front Microbiol. 2013; 4:267.
PMID: 24046765
PMC: 3763195.
DOI: 10.3389/fmicb.2013.00267.
Roddy P, Howard N, Van Kerkhove M, Lutwama J, Wamala J, Yoti Z
PLoS One. 2013; 7(12):e52986.
PMID: 23285243
PMC: 3532309.
DOI: 10.1371/journal.pone.0052986.
Viral hemorrhagic fevers: advancing the level of treatment.
Ippolito G, Feldmann H, Lanini S, Vairo F, Di Caro A, Capobianchi M
BMC Med. 2012; 10:31.
PMID: 22458265
PMC: 3325866.
DOI: 10.1186/1741-7015-10-31.
Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.
Marzi A, Feldmann H, Geisbert T, Falzarano D
J Bioterror Biodef. 2012; S1(4).
PMID: 22288023
PMC: 3265573.
DOI: 10.4172/2157-2526.S1-004.
Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.
Marzi A, Ebihara H, Callison J, Groseth A, Williams K, Geisbert T
J Infect Dis. 2011; 204 Suppl 3:S1066-74.
PMID: 21987743
PMC: 3203393.
DOI: 10.1093/infdis/jir348.
Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection.
Cilloniz C, Ebihara H, Ni C, Neumann G, Korth M, Kelly S
J Virol. 2011; 85(17):9060-8.
PMID: 21734050
PMC: 3165855.
DOI: 10.1128/JVI.00659-11.
Filovirus vaccines.
Bradfute S, Dye Jr J, Bavari S
Hum Vaccin. 2011; 7(6):701-11.
PMID: 21519188
PMC: 3219077.
DOI: 10.4161/hv.7.6.15398.
Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies.
de Wit E, Feldmann H, Munster V
Genome Med. 2011; 3(1):5.
PMID: 21349211
PMC: 3092090.
DOI: 10.1186/gm219.
Progress in filovirus vaccine development: evaluating the potential for clinical use.
Falzarano D, Geisbert T, Feldmann H
Expert Rev Vaccines. 2010; 10(1):63-77.
PMID: 21162622
PMC: 3398800.
DOI: 10.1586/erv.10.152.
Ebola haemorrhagic fever.
Feldmann H, Geisbert T
Lancet. 2010; 377(9768):849-62.
PMID: 21084112
PMC: 3406178.
DOI: 10.1016/S0140-6736(10)60667-8.
Prospects for immunisation against Marburg and Ebola viruses.
Geisbert T, Bausch D, Feldmann H
Rev Med Virol. 2010; 20(6):344-57.
PMID: 20658513
PMC: 3394174.
DOI: 10.1002/rmv.661.
Comparative pathogenesis and systems biology for biodefense virus vaccine development.
Bowick G, Barrett A
J Biomed Biotechnol. 2010; 2010:236528.
PMID: 20617142
PMC: 2896660.
DOI: 10.1155/2010/236528.
Postexposure treatment of Marburg virus infection.
Geisbert T, Hensley L, Geisbert J, Leung A, Johnson J, Grolla A
Emerg Infect Dis. 2010; 16(7):1119-22.
PMID: 20587184
PMC: 3321919.
DOI: 10.3201/eid1607.100159.
Are we any closer to combating Ebola infections?.
Feldmann H
Lancet. 2010; 375(9729):1850-2.
PMID: 20511001
PMC: 3398603.
DOI: 10.1016/S0140-6736(10)60597-1.
Ebolavirus glycoprotein structure and mechanism of entry.
Lee J, Saphire E
Future Virol. 2010; 4(6):621-635.
PMID: 20198110
PMC: 2829775.
DOI: 10.2217/fvl.09.56.
